<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (iDLBCL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is a newly categorized <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in the WHO Classification of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> of Haematopoietic and Lymphoid Tissues v4 </plain></SENT>
<SENT sid="1" pm="."><plain>This <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has characteristics of both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, morphologically and genetically </plain></SENT>
<SENT sid="2" pm="."><plain>We report a case with therapy-resistant iDLBCL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, which used to be categorized as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in the WHO Classification v3 </plain></SENT>
<SENT sid="3" pm="."><plain>This case showed strong BCL2 staining, otherwise exhibiting features of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The case was treated with intensive chemotherapy containing high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>However, soon after the chemotherapy, the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> relapsed in the central <z:mp ids='MP_0008912'>nervous</z:mp> system and was resistant to whole-brain radiation therapy and allogeneic stem cell transplantation </plain></SENT>
<SENT sid="6" pm="."><plain>The patient died 37 days after the transplantation </plain></SENT>
<SENT sid="7" pm="."><plain>The clinical course was different from that of typical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in terms of resistance to intensive chemotherapy, in agreement with the characteristics of iDLBCL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>